Extrapolation of Data From the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) Further Highlights the Survival Benefit of Tafamidis in Transthyretin Amyloid Cardiomyopathy
Journal of Cardiac Failure - United States
doi 10.1016/j.cardfail.2019.07.216
Full Text
Open PDFAbstract
Available in full text
Date
August 1, 2019
Authors
Publisher
Elsevier BV